A first clinical trial for a drug against Duchenne Muscular Dystrophy. Click here.
A first clinical trial in Yvelines for the treatment of Duchenne Muscular Dystrophy. Click here.
The launch of the first clinical trial using exon skipping with an antisense oligonucleotide of the tricyclo-DNA class for the treatment of Duchenne Muscular Dystrophy
After receiving an approval from the French health regulatory authority ANSM for its "AVANCE 1" clinical trial, SQY Therapeutics, a French biotech, announces today the start of patient enrollment for the First-In-Human administration of the investigational medicinal product SQY51, a new generation of antisense oligonucleotide designed to restore semi-functional dystrophin by skipping exon 51 of …